QGEN|Qiagen NV|Price:32.690|Chg%:-1.01

More Details of Qiagen NV Company

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Qiagen NV Info



Ticker SymbolQGEN

Company nameQiagen NV

IPO dateSep 01, 1996

CEOBernard (Thierry)

Number of employees5765

Security typeOrdinary Share

Fiscal year-endSep 01

AddressHulsterweg 82

CityVENLO

Stock exchangeNASDAQ OMX NASDAQ Basic NYSE

CountryNetherlands

Postal code5912 PL

Phone31773556600

Websitehttps://www.qiagen.com/

Ticker SymbolQGEN

IPO dateSep 01, 1996

CEOBernard (Thierry)

Company Executives of Qiagen NV



Name

Name/Position

Position

Shareholding

Change

Mr. Thierry Bernard

Chief Executive Officer, Managing Director, Member of the Executive Board

374.74K

+20.87%

Mr. Roland Sackers

Managing Director, Chief Financial Officer, Member of the Executive Board

349.19K

-4.22%

Dr. Metin Colpan, Ph.D.

Independent Member of the Supervisory Board

167.23K

+2.41%

Tallett (Elizabeth E)

Independent Member of the Supervisory Board

49.12K

+8.67%

Prof. Dr. Ross L. Levine, M.D.

Independent Member of the Supervisory Board

15.46K

+23.57%

Prof. Dr. Elaine R. Mardis, Ph.D.

Independent Member of the Supervisory Board

3.77K

--

Mr. Stephen H. (Steve) Rusckowski

Independent Chairman of the Supervisory Board

22.00

-4.55%

Dr. Toralf Haag, Ph.D.

Independent Member of the Supervisory Board

--

Dr. Eva Pisa, Ph.D.

Independent Member of the Supervisory Board

--

Mr. Bert van Meurs

Independent Member of the Supervisory Board

--

Name

Name/Position

Position

Shareholding

Change

Mr. Thierry Bernard

Chief Executive Officer, Managing Director, Member of the Executive Board

374.74K

+20.87%

Mr. Roland Sackers

Managing Director, Chief Financial Officer, Member of the Executive Board

349.19K

-4.22%

Dr. Metin Colpan, Ph.D.

Independent Member of the Supervisory Board

167.23K

+2.41%

Tallett (Elizabeth E)

Independent Member of the Supervisory Board

49.12K

+8.67%

Prof. Dr. Ross L. Levine, M.D.

Independent Member of the Supervisory Board

15.46K

+23.57%

Prof. Dr. Elaine R. Mardis, Ph.D.

Independent Member of the Supervisory Board

3.77K

--

Revenue Breakdown

Currency: USDUpdated: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

By BusinessUSD

Name

Revenue

Proportion

Consumables and Related Revenues

1.88B

89.78%

Instrumentation

213.57M

10.22%

By RegionUSD

Name

Revenue

Proportion

United States

998.45M

47.77%

Europe & Middle East & Africa

712.76M

34.10%

Asia, Pacific & Rest of the World

290.73M

13.91%

Other Americas

88.06M

4.21%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Consumables and Related Revenues

1.88B

89.78%

Instrumentation

213.57M

10.22%

Shareholding Stats

Updated: Sun, May 10

Shareholders

Shareholder Types

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

9.24%

MFS Investment Management

7.79%

T. Rowe Price International Ltd

3.88%

The Vanguard Group, Inc.

3.16%

Vanguard Capital Management, LLC

2.96%

Other

72.97%

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

9.24%

MFS Investment Management

7.79%

T. Rowe Price International Ltd

3.88%

The Vanguard Group, Inc.

3.16%

Vanguard Capital Management, LLC

2.96%

Other

72.97%

Shareholder Types

Shareholders

Proportion

Investment Advisor

39.84%

Investment Advisor/Hedge Fund

28.39%

Research Firm

4.94%

Hedge Fund

2.46%

Pension Fund

1.41%

Bank and Trust

0.63%

Individual Investor

0.46%

Insurance Company

0.07%

Sovereign Wealth Fund

0.04%

Other

21.75%

Institutional Shareholding



Updated: Sun, Apr 5

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q1

1005

161.40M

78.32%

-30.07M

2025Q4

1008

154.25M

74.88%

-44.86M

2025Q3

996

177.81M

82.00%

-32.33M

2025Q2

996

189.55M

87.53%

+6.64M

2025Q1

1017

179.03M

82.67%

+27.58M

2024Q4

1010

129.03M

59.70%

-70.06M

2024Q3

1010

183.22M

84.72%

-23.62M

2024Q2

1002

184.34M

84.75%

+8.40M

2024Q1

988

165.20M

76.61%

-7.18M

2023Q4

993

165.11M

76.72%

-10.52M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

BlackRock Institutional Trust Company, N.A.

29.26M

14.2%

+9.77M

+50.17%

Mar 20, 2026

MFS Investment Management

16.06M

7.79%

-5.86M

-26.74%

Jan 08, 2026

T. Rowe Price International Ltd

8.01M

3.89%

+861.26K

+12.05%

Dec 31, 2025

The Vanguard Group, Inc.

6.51M

3.16%

-2.46M

-27.38%

Mar 18, 2026

EARNEST Partners, LLC

3.98M

1.93%

-19.48K

-0.49%

Dec 31, 2025

Amundi Asset Management, SAS

3.92M

1.9%

-22.49K

-0.57%

Dec 31, 2025

Boston Partners

3.78M

1.83%

-33.85K

-0.89%

Dec 31, 2025

T. Rowe Price Associates, Inc.

3.33M

1.61%

-4.28K

-0.13%

Jan 31, 2026

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

First Trust Nasdaq Lux Digi Health Solutions ETF

4.04%

Global X Genomics & Biotechnology ETF

3.81%

Invesco Biotechnology & Genome ETF

2.54%

VanEck Biotech ETF

1.79%

ROBO Global Healthcare Technology & Innovation ETF

1.51%

Pacer US Large Cap Cash Cows Growth Leaders ETF

1.26%

iShares Health Innovation Active ETF

1.21%

First Trust Health Care Alphadex Fund

0.91%

Franklin Genomic Advancements ETF

0.86%

WisdomTree International Multifactor Fund

0.72%

First Trust Nasdaq Lux Digi Health Solutions ETF

Proportion4.04%

Global X Genomics & Biotechnology ETF

Proportion3.81%

Invesco Biotechnology & Genome ETF

Proportion2.54%

VanEck Biotech ETF

Proportion1.79%

ROBO Global Healthcare Technology & Innovation ETF

Proportion1.51%

Pacer US Large Cap Cash Cows Growth Leaders ETF

Proportion1.26%

iShares Health Innovation Active ETF

Proportion1.21%

First Trust Health Care Alphadex Fund

Proportion0.91%

Franklin Genomic Advancements ETF

Proportion0.86%

WisdomTree International Multifactor Fund

Proportion0.72%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

May 12, 2026

QGEN.NB Final Cash Dividend of gross USD 0.35 paid on Jul 14, 2026 going ex on Jul 07, 2026

Jul 07, 2026

Jul 14, 2026

Jul 07, 2026

May 07, 2025

QGEN.NB Final Cash Dividend of gross USD 0.25 paid on Jul 10, 2025 going ex on Jul 02, 2025

Jul 02, 2025

Jul 10, 2025

Jul 02, 2025

Stock Splits



Date

Ex-dividend Date

Type

Ratio

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 18, 2024

Merger

25→24.25

Jan 18, 2024

Merger

25→24.25

Date

Ex-dividend Date

Type

Ratio

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 18, 2024

Merger

25→24.25

Jan 18, 2024

Merger

25→24.25

Jan 18, 2024

Merger

25→24.25

Jan 18, 2024

Merger

25→24.25